UNITED
        STATES
 SECURITIES
        AND EXCHANGE COMMISSION
 Washington,
        D.C. 20549
 
 FORM
        10-KSB/A
 (Amendment
        No. 1)
 
 (Mark
        One)
  x
        Annual Report Pursuant
        to Section 13 or 15(d) of The Securities Exchange Act
        of
        1934
 
 For
        the
        Fiscal Year Ended December 31, 2006
 
 o Transition
        Report
        Pursuant to Section 13 or 15(d) of The Securities Exchange
        Act of 1934
 
 Commission
        File Number 000-51140
 
 **CURATECH
        INDUSTRIES, INC.**
 (Name
        of
        small business issuer in its charter)
  Nevada
                87-0649332(State
                    or other jurisdiction of
                I.R.S.
                    Employerincorporation
                    or organization)
                Identification
                    No.)
 6337
        Highland Drive, #1053, Salt Lake City, Utah 84121
 (Address
        of principal executive offices) (Zip Code)
 
 Issuer's
        telephone no.: (801) 616-2355
 
 Securities
        registered pursuant to Section 12(b) of the Exchange Act: None
 
 Securities
        registered pursuant to Section 12(g) of the Exchange Act: Common Stock, $0.001
        par value
 
 Check
        whether the issuer (1) filed all reports required to be filed by Section
        13 or
        15(d) of the Exchange Act during the past 12 months (or for such shorter
        period
        that the registrant was required to file such reports), and (2) has been
        subject
        to such filing requirements for the past 90 days. Yes x No o
 
 Check
        if
        there is no disclosure of delinquent filers in response to Item 405 of
        Regulation S-B contained in this form, and no disclosure will be contained,
        to
        the best of the Registrant's knowledge, in definitive proxy or information
        statements incorporated by reference in Part III of this Form 10-KSB or any
        amendment to this Form 10-KSB. o
 
 Indicate
        by check mark whether the registrant is a shell company (as defined in Rule
        12b-2 of the Exchange Act).
 Yes o
        No x
  State
        the
        issuer's revenues for its most recent fiscal year. $ -0-
 
 State
        the
        aggregate market value of the voting stock held by non-affiliates computed
        by reference to the price at which the stock was sold, or the average bid
        and
        ask prices of such stock as of a specified date within 60 days. As of April
        13,
        2007, the aggregate value of the voting stock held by non-affiliates was
        $14,451,904 based upon approximately 6,881,859 shares held by non-affiliates,
        and the average of the bid price ($1.80 per share) and the asked price ($2.40)
        per share of $2.10 per share.
 
 State
        the
        number of shares outstanding of each of the issuer's classes of common equity,
        as of the latest practicable date.
  Class
                Outstanding
                    as of April 13, 2007Common
                    Stock, Par Value $0.001
                16,760,199
                    shares
  DOCUMENTS
        INCORPORATED BY REFERENCE
 
 A
        description of "Documents Incorporated by Reference" is contained in Part
        III,
        Item 13.
 
 Transitional
        Small Business Disclosure Format. Yes o No x
  Explanatory
        Note Regarding Amendment:
 
 The
        Company’s Annual Report on Form 10-KSB for the year ended December 31, 2006
        originally filed on April 17, 2007 has been
        amended in response to a comment letter from the Securities and Exchange
        Commission (“Commission”) dated May 4, 2007.
 
 The
        purpose of this amendment is to make those changes in the Annual Report that
        are
        necessary to adequately address the Commission’s comments, including: (i) a
        restatement to the Company’s financial statements to account for the 2006
        acquisition of MedaCure International, Inc. (“MedaCure”) by the Company as a
        reverse acquisition, with MedaCure presented as the accounting acquirer;
        (ii) to
        revise the information included in Management’s Discussion and Analysis or Plan
        of Operation in Item 6 to reflect the revised financial statements; (iii)
        to add
        additional information in Executive Compensation Item 10 concerning the
        compensation of officers and directors; and (iv) to add additional information
        in the financial statement footnotes explaining the nature of the impairment
        of
        assets and to add information concerning the existence of a control
        relationship. The information in this report is current as of December 31,
        2006,
        unless otherwise specified.
  
  CURATECH
        INDUSTRIES, INC.
 
 TABLE
        OF
        CONTENTS
  PagePART
                    IItem
                    1.
                Description
                    of Business
                3Item
                    2.
                Description
                    of Property
                12Item
                    3.
                Legal
                    Proceedings
                12Item
                    4.
                Submission
                    of Matter to a Vote of Security Holders
                12PART
                    IIItem
                    5.
                Market
                    for Common Equity and Related Stockholder Matters
                12Item
                    6.
                Management's
                    Discussion and Analysis or Plan of Operation
                14Item
                    7.
                Financial
                    Statements
                18Item
                    8.
                Changes
                    in and Disagreements with Accountants on Accounting and Financial
                    Disclosure
                28Item
                    8A.
                Controls
                    and Procedures
                28Item
                    8B
                Other
                    Information
                28PART
                    IIIItem
                    9.
                Directors,
                    Executive Officers, Promoters and Control Persons;Compliance
                    with Section
                    16(a) of the Exchange Act
                29Item
                    10.
                Executive
                    Compensation
                31Item
                    11.
                Security
                    Ownership of Certain Beneficial Owners and Management and Related
                    Stockholder Matters
                33Item
                    12.
                Certain
                    Relationships and Related Transactions
                34Item
                    13.
                Exhibits
                35Item
                    14.
                Principal
                    Accountant Fees and Services
                36Signatures
                37
 2
  **PART
        I**
 
 **Item
        1. Description of Business**
  Business
        Development
 
 **History**
 
 On
        March
        3, 2000, the board of directors of our former parent corporation, Draco Holding
        Corporation, unanimously approved the formation of Jump'n Jax, Inc., a Utah
        corporation ("Jump'n Jax")(“the Company”), as a wholly-owned subsidiary of the
        Draco. Jump'n Jax operated its business of leasing inflatable balloon
        bounce-houses for parties and outdoor activities in Southern Utah.
 
 From
        its
        formation in March 2000, Jump'n Jax consistently incurred operating losses, with only a few exceptions where
        it
        showed nominal profits. We financed ongoing operations through various loans
        and
        contributions made by two persons who then served as officers of the Company,
        Messrs. Clissold and Moulton.
 
 On
        January 1, 2006, the board of directors elected to officially cease our bounce
        house operations. This decision was due, in part, to the lack of profitability
        of the operations and the resignation of the primary bounce house operator.
        We
        are deemed to have re-entered the development stage on January 1, 2006.
 
 On
        October 26, 2006, we completed the acquisition of MedaCure International,
        Inc.,
        a Nevada corporation located in Salt Lake City, Utah (“MedaCure”). The
        acquisition was consummated pursuant to an agreement entered into on June
        22,
        2006, whereby we agreed to merge our newly created, wholly-owned subsidiary,
        CuraTech Acquisitions, Inc., with and into MedaCure with MedaCure being the
        surviving entity as our wholly owned subsidiary.
 
 Prior
        to
        completion of the acquisition, on October 4, 2006 we effected a 4 shares
        for 1
        share forward stock split of our issued and outstanding shares of common
        stock
        and changed our corporate name to CuraTech Industries, Inc. As a result of
        the
        forward stock split, our outstanding shares of common stock increased from
        807,602 shares to 3,230,408 shares. We have also changed our corporate domicile
        from the State of Utah to Nevada.
 
 Under
        the
        terms of the merger agreement, we issued an aggregate of approximately
        12,342,239 shares of our common stock, post-split, to the stockholders of
        MedaCure. MedaCure is now a wholly-owned subsidiary of the Company. Also,
        we
        have added to our board of directors three new directors nominated by
        MedaCure.
 
 **Business
        of MedaCure International, Inc.**
 
 MedaCure
        was organized as a Nevada corporation by Shirlee Dastrup on April 25, 2006
        for
        the purpose of acquiring, developing and marketing a certain health supplement
        that is believed to enhance and build-up the body’s natural immune system
        defenses in both humans and animals. Initially, MedaCure intends to commence
        commercial marketing of its supplement primarily outside the U.S. Initial
        marketing in the U.S. will primarily be to the veterinarian market for use
        in
        treating animals. MedaCure is also looking at the possibility of initiating
        a
        collaboration and partnering program that will focus on developing business
        alliances designed to generate sales, applications and marketing
        opportunities.
 
 MedaCure
        acquired its product pursuant to a purchase agreement in May 2006 from the
        inventor, Dr. William Stacey. Under the terms of the agreement, MedaCure
        acquired all formulas, recipes and manufacturing and marketing rights relating
        to the product in consideration for $150,000 and 537,500 shares of MedaCure
        common stock. Dr. Stacey will serve as a consultant MedaCure’s business and the
        further development and eventual manufacturing and marketing of the product.
  3
  Presently
        MedaCure maintains its office at 6337 Highland Drive, # 1053, Salt Lake City,
        Utah 84121, and its telephone number is (801) 616-2355. Management intends
        to
        consider establishing corporate headquarters, manufacturing base and laboratory
        facilities in Orem, Utah, located just south of Salt Lake City.
 
 **Product**
 
 The
        MedaCure supplement is manufactured using a variety of components that are
        either natural or previously FDA approved ingredients. The combination of
        the
        components has not been approved by the FDA. MedaCure believes that the
        supplement is applicable to both humans and animals and can cause the body’s
        immune system to re-awaken from a state of suppression that can occur due
        to
        numerous factors including genetic predisposition, types of foods a person
        eats
        and environmental contamination. MedaCure also believes that the supplement
        can
        modulate the body’s immune system allowing the system to better fight diseases
        naturally by attacking infections from pathogens (disease producing
        organisms).
 
 The
        immune system is a complex network of specialized organs, glands and cells
        that,
        when working properly, protect the body from pathogens such as virus, bacteria,
        fungus and other foreign tissues. The MedaCure supplement is based on the
        theory
        that certain chemicals found on the surface of the T 4 lymphocyte (a “helper”
white blood cell) attract pathogens. Activation of the T4 is critical to
        the
        activation of the immune response. Activation takes place when the T4 cell
        recognizes the antigen displayed by the invading pathogen. An antigen is
        the
        substance to which the body reacts by producing antibodies. The function
        of the
        T4 is to act as a control for the rest of the immune system. Once activated,
        the
        T4 cell produces immune proteins that in turn activate the “killer” cells. The T
        4 directs and coordinates these other killer cells of the immune system that
        do
        the actual killing of the specific antigen producing pathogen and protects
        the
        body. This is done by chemical signals passed from one cell to another or
        chemical signals released into the blood stream.
 
 Once
        infected by a pathogen, the T4 no longer sends out the proper signals to
        stimulate other cells. The pathogen is attracted to the very spot where the
        T4
        receives messages from other cells. These spots are called "receptors." As
        the
        disease progresses, more and more T4 lymphocytes are infected and can no
        longer
        receive messages that tell it the body is infected. Slowly the body's ability
        to
        fight off infection declines.
 
 MedaCure
        believes that its product increases the cells that kill infected cells and
        increases cells that protect the bodies from infection. The supplement is
        designed to break the attraction the pathogen has for the T4 lymphocyte receptor
        site. Once the T4 is free of the pathogen it can again send the proper signals
        to the other cells of the immune system.
 
 MedaCure’s
        supplement can be used by both humans and animals. In humans, it can be taken
        intraveneously (IV), sublingual, orally or by topical cream. IV application
        requires FDA approval, for which MedaCure has not yet applied.
 
 **Manufacturing**
 
 MedaCure
        anticipates that it will require a facility of approximately 5,000 square
        feet
        to manufacture its product. Management anticipates that the facility will
        be
        leased on a long-term basis. The facility must have a sterile environment
        with
        an assembly line capable of mass-producing and packaging the product. The
        facility will also handle shipping of product and receiving materials. Although
        MedaCure has not yet selected the final site for its manufacturing facility,
        it
        has identified the manufacturing equipment and packaging machinery it will
        need
        and estimates that the cost to prepare the site for operation will be
        approximately $150,000.
  4
  **Marketing**
 
 MedaCure
        plans to sell its product to both the health and medical industries as well
        as
        the veterinarian industry. Initially, MedaCure will concentrate on the
        veterinary market in the U.S. MedaCure intends to use direct selling efforts
        through pharmaceutical sales personnel, exhibits, Internet web site,
        presentations at trade shows, scientific meetings, medical conferences, as
        well
        as through networks built up through existing product sales and distributor
        relationships. MedaCure is currently beginning to build a network of
        distributors to promote and market its product. MedaCure also intends to
        establish a collaboration and partnering programs that will focus on developing
        business alliances designed to generate sales, applications and marketing
        opportunities.
 
 MedaCure's
        initial marketing strategy will focus on establishing distributors for a
        licensing fee. Those territories on which MedaCure will concentrate will
        include
        North America (which includes United States and Canada) and Mexico. As business
        warrants and funds are available, MedaCure intends to expand its marketing
        into
        South America, Europe and other parts of the world.
 
 **Intellectual
        Property and Patent Protection**
 
 MedaCure
        does not presently have any patents related to its product, but intends to
        aggressively defend and expand its intellectual property and technology by
        applying for patent and/or copyright protection in the future as deemed
        necessary. We intend to examine and determine the necessity to secure
        comprehensive intellectual property coverage in the United States and in
        the
        most relevant foreign markets in anticipation of future commercialization
        opportunities. MedaCure also intends to rely on trade secrets, common law
        trademark rights and trademark registrations, and will continue to protect
        its
        intellectual property via non-disclosure agreements, license agreements and
        limited information distribution.
 
 **Facilities**
 
 MedaCure
        currently occupies office facilities in Salt Lake City, Utah consisting of
        approximately 500 square feet of office space. Management is presently looking
        for a manufacturing facility, most likely in Orem, Utah, that is located
        approximately 35 miles south of Salt Lake City. Once it locates an appropriate
        laboratory and production facility, MedaCure will most likely move its principal
        offices to that location. Management believes that it will locate and secure
        an
        acceptable facility in the second quarter of 2007. It is estimated that MedaCure
        will need a facility of at least 5,000 square feet that is capable of housing
        a
        sterile manufacturing operation.
 
 **Employees**
 
 MedaCure
        presently has three full time employees and one consultant, but anticipates
        adding employees as it establishes its laboratory and production facilities.
        MedaCure’s employees are not members of any union, nor have they entered into
        any collective bargaining agreements, nor is it anticipated in the near future.
        It is believed that MedaCure’s relationship with its employees is
        good.
  5
  **Government
        Regulations**
 
 MedaCure’s
        supplement and its related promotional and marketing activities are subject
        to
        extensive governmental regulation by numerous domestic and foreign governmental
        agencies and authorities, including the FDA, the FTC, the Consumer Product
        Safety Commission, the United States Department of Agriculture, state attorneys
        general and other state regulatory agencies, and similar government agencies
        in
        each country in which we intend to operate. These regulations can limit our
        ability to import products into new markets and can delay introductions of
        new
        products into existing markets as we attempt to comply with the registration
        and
        approval process for our products.
 
 MedaCure’s
        product may be strictly regulated in certain markets in which MedaCure intends
        to operate. These markets have varied regulations that apply to and distinguish
        nutritional health supplements from “drugs” or “pharmaceutical products.” For
        example, the FDA of the United States under the Federal Food, Drug and Cosmetic
        Act regulates the product. The Federal Food, Drug and Cosmetic Act has been
        amended several times with respect to nutritional supplements, most recently
        by
        the Nutrition Labeling and Education Act and the Dietary Supplement Health
        and
        Education Act. The Dietary Supplement Health and Education Act establishes
        rules
        for determining whether a product is a dietary supplement. Under this statute,
        dietary supplements are regulated more like foods than drugs, are not subject
        to
        the food additive provisions of the law, and are generally not required to
        obtain regulatory approval prior to being introduced to the market. None
        of this
        limits, however, the FDA’s power to remove an unsafe substance from the market.
        In the event a product, or an ingredient in a product, is classified as a
        drug
        or pharmaceutical product in any market, we would generally not be able to
        distribute that product in that market through our distribution channel because
        of strict restrictions applicable to drug and pharmaceutical products.
 
 Most
        existing major markets also regulate product claims and advertising regarding
        the types of claims and representations that can be made regarding the efficacy
        of products, particularly dietary supplements. Accordingly, these regulations
        can limit MedaCure’s ability to inform consumers of the full benefits of its
        product. For example, in the United States, MedaCure is unable to make any
        claim
        that its supplement will diagnose, cure, mitigate, treat or prevent disease.
        The
        Dietary Supplement Health and Education Act permits only substantiated, truthful
        and non-misleading statements of nutritional support to be made in labeling,
        such as statements describing general well-being resulting from consumption
        of a
        dietary ingredient or the role of a nutrient or dietary ingredient in affecting
        or maintaining a structure or a function of the body. In addition, all product
        claims must be substantiated.
 
 **Risk
        Factors**
 
 *You
        should carefully consider the risks and uncertainties described below and
        other
        information in this report. If any of the following risks or uncertainties
        actually occur, our business, financial condition and operating results,
        would
        likely suffer. Additional risks and uncertainties, including those not yet
        identified or that we currently believe are immaterial, may also adversely
        affect our business, financial condition or operating results.*
  6
  **Risks
        Relating to Our Business as a Result of the MedaCure
        Acquisition**
 
 ***We
        will require additional financing to proceed with MedaCure’s business
        activities. There can be no assurance that financing will be available on
        terms
        beneficial to us, or at all.***
 
 MedaCure
        was recently formed and does not have an operating history. We estimate that
        we
        will need financing of approximately $500,000 during the next 12 months to
        proceed with our anticipated business activities. If we need to raise additional
        capital by selling equity or equity-linked securities, these securities would
        dilute the ownership percentage of our existing stockholders. Also, these
        securities could have rights, preferences or privileges senior to those of
        our
        common stock. If we raise additional capital by issuing debt securities,
        those
        securities may contain covenants that restrict us in terms of how we operate
        our
        business, which could also affect the value of our common stock. Without
        additional funding, we may not be able to achieve profitable operations of
        MedaCure, which would most likely have a material negative impact on our
        business and future prospects. There can be no assurance that we will be
        able to
        raise future capital on terms that will be reasonable and beneficial to us,
        or
        at all.
 
 ***MedaCure
        has a limited operating history and has not recorded revenues or operating
        profits since its inception. Continuing losses may exhaust our capital resources
        and force us to discontinue operations.***
 
 MedaCure
        was incorporated in April 2006, has a limited operating history and incurred
        net
        losses since inception. Jump’n Jax, Inc., now known as CuraTech Industries,
        Inc., has been in operation since March 2000, but has realized only nominal
        revenues in recent years and has a net stockholders’ equity of only $47,051 as
        of December 31, 2006. The potential for us to generate future profits depends
        on
        many factors, including the following:
 
 ·
              our
                  ability to secure adequate funding to complete ongoing research
                  and
                  development and to commercially market MedaCure’s
                  product;
 ·
              the
                  size and timing of future customer orders, milestone achievement,
                  product
                  delivery and customer acceptance, if
                  required;
 ·
              success
                  in developing, maintaining and enhancing strategic relationships
                  with
                  potential customers;
 ·
              our
                  ability to protect MedaCure’s intellectual
                  property;
 ·
              actions
                  by competitors towards the development and marketing of products
                  that will compete directly with
                  ours;
 ·
              the
                  costs of maintaining and expanding operations;
                  and
 ·
              our
                  ability to attract and retain a qualified work
                  force.
 
 There
        can
        be no assurance that we will achieve any of the foregoing factors or realize
        profitability in the immediate future, or at any time.
 
 ***If
        we cannot achieve commercial application of MedaCure’s product, we may not
        achieve profitability.***
 
 The
        development of a market for MedaCure’s product is dependent on the creation and
        implementation of a successful marketing plan and the acceptance of the product
        in the marketplace. This development may be impacted by many factors including,
        but not limited to the following:
 
 ·
              existence
                  of competing products and emergence of new
                  products;
 
 ·
              inability
                  to finalize a successful marketing
                  strategy;
 7
  ·
              lack
                  of acceptance of MedaCure’s product;
                  and
 ·
              inability
                  to adjust to changes in the marketplace and to keep pace with with
                  competitors.
 
 If
        we
        fail to develop adequate market for MedaCure’s product or if we are unable to
        successfully compete with other existing and new products, we may not achieve
        profitability.
 
 ***Certain
        government regulations concerning approval of MedaCure’s products may negatively
        impact our business following the acquisition of
        MedaCure.***
 
 It
        may be
        necessary MedaCure’s product to be approved by one or more agencies of the
        Federal government, including the Food and Drug Administration. Government
        regulations concerning the product and its use by humans may be burdensome
        and
        costly and could negatively impact our business following the acquisition
        of
        MedaCure. Although we believe the product does not require FDA approval for
        the
        initial application in the U.S. for animal treatment, we do not know the
        extent
        to which any such regulations may impact the product or MedaCure’s business. Any
        new regulation may increase costs and could reduce our potential to be
        profitable following completion of the merger.
 
 ***The
        industry in which MedaCure operates is highly competitive and could affect
        our
        results of operations, which would make profitability even more difficult
        to
        achieve and sustain.***
 
 The
        health and supplement industry is highly competitive and is marked by rapid
        changes and new products. Other competitors and potential competitors include
        several large national and international companies involved in the health
        and
        supplement business. Most existing and potential competitors have greater
        financial resources, larger market share, and larger production and technology
        research capability, which may enable them to establish a stronger competitive
        position than we have, in part through greater marketing opportunities. If
        we
        fail to address competitive developments quickly and effectively, we will
        not be
        able to grow our business or remain a viable entity.
 
 ***Our
        business could be adversely affected by any adverse economic developments
        in the
        health and supplement industry and/or the economy in general.***
 
 MedaCure
        depends on the perceived initial demand for its product in the U.S. in the
        treatment of animals. Therefore, our business is susceptible to downturns
        in the
        health and supplement industry and the economy in general. Any significant
        downturn in the market or in general economic conditions would likely hurt
        our
        business.
 
 ***If
        we fail to keep up with changes affecting the MedaCure product and the markets
        that we will ultimately offer the product, we will become less competitive
        and
        thus adversely affect future financial performance.***
 
 In
        order
        to remain competitive and serve its potential effectively, we must respond
        on a
        timely and cost-efficient basis to changes in health and supplement products
        in
        general, industry standards and procedures and customer preferences. Management
        believes that to remain competitive, we will need to continuously develop
        new
        products and applications for existing products. In some cases these changes
        may
        be significant and the cost to comply with these changes may be substantial.
        We
        cannot assure you that we will be able to adapt to any changes in the future
        or
        that we will have the financial resources to keep up with changes in the
        marketplace. Also, the cost of adapting to changes in MedaCure’s product may
        have a material and adverse effect on our operating results.
  8
  ***Our
        business could be adversely affected by local, state, national, international
        laws or regulations.***
 
 Our
        future success depends in part on laws and regulations that exist, or are
        expected to be enacted around the world. These laws and regulations could
        negatively affect our business and anticipated revenues. We cannot guarantee
        a
        positive outcome in direction, timing, or scope of laws and regulations that
        may
        be enacted which will affect our business.
 
 ***Our
        future success depends on retaining MedaCure’s existing key employees and hiring
        and assimilating new key employees. The loss of key employees or the inability
        to attract new key employees could limit our ability to execute our growth
        strategy, resulting in lost sales and a slower rate of
        growth.***
 
 Our
        future success depends in part on our ability to retain MedaCure’s key employees
        including its executive officers. Although following the acquisition we expect
        to have employment agreements with these executives, each executive may be
        able
        to terminate his or her agreement at any time. We anticipate obtaining in
        the
        futures "key man" insurance for one or more of our key executives. It would
        be
        difficult for us to replace any one of these individuals. In addition, as
        we
        grow we may need to hire additional key personnel. We may not be able to
        identify and attract high quality employees or successfully assimilate new
        employees into our existing management structure.
 
 ***We
        may be unable to protect our intellectual property adequately or cost
        effectively, which may cause us to lose market share or reduce
        prices.***
 
 Our
        future success depends in part on our ability to protect and preserve
        proprietary rights related to MedaCure’s product. We cannot assure you that we
        will be able to prevent third parties from using our intellectual property
        rights and technology without our authorization. Although MedaCure has not
        obtained any patents on its product, it may in the future file for patent
        protection for its product and will also rely on trade secrets, common law
        trademark rights and trademark registrations. We will also employ
        confidentiality and work for hire, development, assignment and license
        agreements with employees, consultants, third party developers, licensees
        and
        customers. However, these measures afford only limited protection and may
        be
        flawed or inadequate. Also, enforcing intellectual property rights could
        be
        costly and time-consuming and could distract management’s attention from
        operating business matters.
 
 ***MedaCure’s
        intellectual property may infringe on the rights of others, resulting in
        costly
        litigation.***
 
 In
        recent
        years, there has been significant litigation in the United States involving
        patents and other intellectual property rights. In particular, there has
        been an
        increase in the filing of suits alleging infringement of intellectual property
        rights, which pressure defendants into entering settlement arrangements quickly
        to dispose of such suits, regardless of their merits. Other companies or
        individuals may allege that we infringe on their intellectual property rights.
        Litigation, particularly in the area of intellectual property rights, is
        costly
        and the outcome is inherently uncertain. In the event of an adverse result
        against future rights we may acquire, we could be liable for substantial
        damages
        and we may be forced to discontinue our use of the subject matter in question
        or
        obtain a license to use those rights or develop non-infringing alternatives.
        Any
        of these results would increase our cash expenditures, adversely affecting
        our
        financial condition.
  9
  ***We
        may not be able to manage future growth effectively, which could adversely
        affect our operations and financial performance.***
 
 The
        ability to manage and operate our business as we execute our development
        and
        growth strategy will require effective planning. Possible future growth could
        strain our management and internal resources and cause other problems that
        could
        adversely affect our financial performance. We expect that our efforts to
        grow
        will place a significant strain on personnel, management systems, infrastructure
        and other resources. Our ability to manage future growth effectively will
        also
        require us to successfully attract, train, motivate, retain and manage new
        employees and continue to update and improve our operational, financial and
        management controls and procedures. If we do not manage our growth effectively,
        our operations could be adversely affected, resulting in slower growth and
        a
        failure to achieve or sustain profitability.
 
 ***Being
        a public company involves increased administrative costs, which could result
        in
        lower net income and make it more difficult for us to attract and retain
        key
        personnel.***
 
 As
        a
        public company, we incur significant legal, accounting and other expenses
        that
        MedaCure did not incur as a private company. In addition, the Sarbanes-Oxley
        Act
        of 2002 as well as new rules subsequently implemented by the SEC, have required
        changes in corporate governance practices of public companies. We expect
        that
        these new rules and regulations will increase our legal and financial compliance
        costs and make some activities more time consuming. For example, in connection
        with being a public company, we may have to create several board committees,
        implement additional internal controls and disclose controls and procedures,
        retain a transfer agent and financial printer, adopt an insider trading policy
        and incur costs relating to preparing and distributing periodic public reports
        in compliance with our obligations under securities laws. These new rules
        and
        regulations could also make it more difficult for us to attract and retain
        qualified executive officers and members of our board of directors, particularly
        to serve on our audit committee.
 
 **Risks
        Relating to Ownership of Our Common Stock**
 
 ***We
        cannot assure you that there will be an active trading market for our common
        stock and it could be difficult for holders of our common stock to liquidate
        their shares.***
 
 Even
        though we expect our common stock to continue to be quoted on the OTC Bulletin
        Board, we cannot predict the extent to which a trading market will develop
        or
        how liquid that market might become. Also, most shares outstanding after
        the
        acquisition of MedaCure, including those issued pursuant to the acquisition,
        are
        deemed "restricted securities" within the meaning of Rule 144 promulgated
        by the
        SEC and will therefore be subject to certain limitations on the ability of
        holders to resell such shares. Because only a small percentage of our
        outstanding shares are freely tradeable in the public market, the price of
        our
        shares could be volatile and liquidation of a person’s holdings may be
        difficult. Thus, holders of our common stock may be required to retain their
        shares for a long period of time.
 
 ***We
        do not anticipate paying dividends in the foreseeable future, which could
        make
        our stock less attractive to potential investors.***
 
 We
        anticipate that we will retain any future earnings and other cash resources
        for
        future operation and development of our business and do not intend to declare
        or
        pay any cash dividends in the foreseeable future. Any future payment of cash
        dividends will be at the discretion of our board of directors after taking
        into
        account many factors, including our operating results, financial condition
        and
        capital requirements. Corporations that pay dividends may be viewed as a
        better
        investment than corporations that do not.
  10
  ***Future
        sales or the potential for sale of a substantial number of shares of our
        common
        stock could cause our market value to decline and could impair our ability
        to
        raise capital through subsequent equity offerings.***
 
 Sales
        of
        a substantial number of shares of our common stock in the public markets,
        or the
        perception that these sales may occur, could cause the market price of our
        common stock to decline and could materially impair our ability to raise
        capital
        through the sale of additional equity securities. In addition to the
        approximately 15,572,647 common shares issued and outstanding at the completion
        of the MedaCure acquisition, there will be approximately another 37 million
        shares of authorized, but unissued common stock that may be issued in the
        future.
 
 ***It
        may be difficult for a third party to acquire us, and this could depress
        our
        stock price.***
 
 Under
        Nevada corporate law, we are permitted to include or exclude certain provisions
        in our articles of incorporation and/or by-laws that could discourage
        information contests and make it more difficult for you and other stockholders
        to elect directors and take other corporate actions. As a result, these
        provisions could limit the price that investors are willing to pay in the
        future
        for shares of our common stock. For example:
 
 ·
              Without
                  prior stockholder approval, the board of directors has the authority
                  to
                  issue one or more classes of preferred stock withrights
                  senior to those of common stock and to determine the rights, privileges
                  and inference of that preferred
                  stock;
 ·
              Under
                  Nevada law, we are not required to provide for, and our by-laws
                  do not provide for, cumulative voting in the election of directors,
                  which
                  would otherwise allow less than a majority of stockholders to elect
                  director candidates; and
 ·
              Stockholders
                  cannot call a special meeting of
                  stockholders.
 
 ***Trading
        in our shares may be subject to certain "penny stock” regulation which could
        have a negative effect on the price of our shares in the public trading
        market.***
 
 Public
        trading of our common stock on the OTCBB may be subject to certain provisions,
        commonly referred to as the penny stock rule, promulgated under the Securities
        Exchange Act of 1934. A penny stock is generally defined to be any equity
        security that has a market price less than $5.00 per share, subject to certain
        exceptions. If our stock is deemed to be a penny stock, trading in our stock
        will be subject to additional sales practice requirements on broker-dealers.
        These may require a broker dealer to:
 
 ·
              make
                  a special suitability determination for purchasers of penny
                  stocks;
 ·
              receive
                  the purchaser's written consent to the transaction prior to
                  the purchase; and
 ·
              deliver
                  to a prospective purchaser of a penny stock, prior to the first
                  transaction, a risk disclosure document relating to the penny stock
                  market.
 
 Consequently,
        penny stock rules may restrict the ability of broker-dealers to trade and/or
        maintain a market in our common stock. Also, many prospective investors may
        not
        want to get involved with the additional administrative requirements, which
        may
        have a material adverse effect on the trading of our shares.
  11
  **Item
        2. Description of Property**
 
 We
        do not
        presently own any property. MedaCure currently occupies office facilities
        in
        Salt Lake City, Utah consisting of approximately 500 square feet of office
        space. Management is presently looking for a manufacturing facility, most
        likely
        in Orem, Utah, that is located approximately 35 miles south of Salt Lake
        City.
        Once it locates an appropriate laboratory and production facility, MedaCure
        will
        most likely move its principal offices to that location. Management believes
        that it will locate and secure an acceptable facility in the second quarter
        of
        2007. It is estimated that MedaCure will need a facility of at least 5,000
        square feet that is capable of housing a sterile manufacturing
        operation.
  **Item
        3. Legal Proceedings**
 
 There
        are
        no material pending legal proceedings to which we or our subsidiary is a
        party
        or to which any of our property is subject and, to the best of our knowledge,
        no
        such action against us is contemplated or threatened.
  **Item
        4. Submission of Matters to a Vote of Security Holders**
 
 On
        June
        22, 2006, our two principal shareholders approved the acquisition of Medacure
        International, Inc. and authorized the issuance of 12,342,239 shares of the
        Company’s common stock to consummate the acquisition. Pursuant to this
        acquisition, the principal shareholders also approved a stock split on a
        four
        shares for one share (4 for 1) basis, and a change in the Company’s corporate
        name to Curatech Industries, Inc. The two shareholders voted a total of
        6,268,000 shares representing approximately 87% of our outstanding voting
        securities, to authorize the reverse split. This action by written consent
        was
        reported to the SEC by the filing of an Information Statement, which was
        also
        sent to all shareholders prior to the effective date of the reverse
        split.
 
 No
        matter
        was submitted to a vote of our security holders, through the solicitation
        of
        proxies or otherwise, during the fourth quarter of the fiscal year covered
        by
        this report.
  **PART
        II**
 
 **Item
        5. Market for Common Equity and Related Stockholder
        Matters**
 
 **Market
        Information**
 
 Our
        common stock is currently included on the OTC Bulletin Board under the symbol
        “CUTC.OB” (previously “JMPJ”). The shares are thinly traded and a limited market
        presently exists for the shares. The following table describes, for the
        respective periods indicated, the prices of the Company common stock in the
        over-the-counter market, based on inter-dealer bid prices, without retail
        mark-up, mark-down or commissions and may not necessarily represent actual
        transactions. The quotations have been provided by market makers in common
        stock
        and/or Pink Sheets LLC.
  12
  Quarter
                    ended
                
                High
                    bid
                
                Low
                    bidMarch
                    31, 2005
                
                $
                0.75
                
                $
                0.255June
                    30, 2005
                
                $
                1.01
                
                $
                0.09September
                    30, 2005
                
                $
                0.15
                
                $
                0.10December
                    31, 2005
                
                $
                1.65
                
                $
                0.62March
                    31, 2006
                
                $
                2.00
                
                $
                1.15June
                    30, 2006
                
                $
                5.25
                
                $
                1.50September
                    30, 2006
                
                $
                10.10
                
                $
                4.50December
                    31, 2006
                
                $
                5.55
                
                $
                1.35
  The
        prices listed in the table above have been adjusted to effect the 4 for 1
        forward stock split of the Company’s shares that occurred on October 4, 2006 and
        the 1 for 12 reverse stock split that occurred October 10, 2005.
 
 **Stockholders**
 
 Presently
        we have approximately 87 holders of record of our common stock. This
        number does not take into consideration stockholders whose shares are held by
        broker-dealers, financial institutions or other nominees.
 
 **Dividend
        Policy**
 
 We
        have
        never declared or paid cash dividends or made distributions in the past
        and
        do not anticipate paying cash dividends or making distributions in the foreseeable
        future. We currently intend to retain and invest future earnings to finance
        operations. There are no material restrictions limiting, or that are likely
        to
        limit, The Company = s
        ability
        to pay dividends on our securities, except for any applicable limitations
        under
        Nevada corporate law.
 
 **Recent
        sales of unregistered securities**
 
 During
        the past three years ended December 31, 2006, The Company has not sold any
        shares of its common stock without registration under the Securities Act
        of
        1933, except for the following:
 
 (1) On
        May 20, 2005, the board of directors authorized the issuance of a total of
        1,333,336 post-split shares (“the issuance”) of common stock, separately, to
        Lane S. Clissold (666,668) and Steven D. Moulton (666,668), two of the Company’s
        former officers. The shares were issued in consideration for Messrs. Clissold's
        and Moulton's agreement to convert into shares of common stock all amounts
        due
        and owing to them resulting from loans and/or advances made to the Company.
        As a
        result of the issuance, the loans and/or advances made by Messrs. Clissold
        and
        Moulton to the Company through May 15, 2005, and all accrued interest thereon,
        were deemed to be paid in full. The shares were valued at $0.1935 per share
        for
        total consideration of $64,500
 
 (2)  On
        May
        25, 2005, the Company authorized the issuance of 133,332 post-split shares
        of
        common stock to an unrelated individual pursuant to a service agreement as
        consideration for services rendered to the Company. The shares valued at
        $0.03
        per share for total consideration of $4,000.
 
 (3)  In
        May
        2006, the Company issued 800,000 common shares to an unrelated third party
        in
        exchange for services rendered and $30,000 in cash.
  13
  (4)  In
        October 2006 the Company issued an aggregate of 12,342,239 shares of common
        stock to approximately 54 persons as consideration for the acquisition of
        MedaCure International, Inc.
 
 In
        each
        transaction, the shares were issued without registration pursuant to Section
        4(2) of the Securities Act of 1933 and/or Rule 506 of Regulation D for a
        transaction not involving any public offering. The certificates representing
        the
        shares were given a restricted legend.
  **Item
        6. Management's Discussion and Analysis or Plan of
        Operation**
 
 The
        following information should be read in conjunction with the financial
        statements and notes thereto appearing elsewhere in this Form
        10-KSB.
 
 **Plan
        of Operation**
 
 Following
        the formation of the Company in March 2000, the Company operated its business
        of
        inflatable balloon bounce-houses for parties and outdoor activities in Southern
        Utah until approximately January 2006, when the Board of directors elected
        to
        cease bounce house operations due, in part, to the lack of profitability
        and the
        resignation of the primary bounce house operator.
 
 Following
        the completion of the acquisition of MedaCure on October 26, 2006, we have
        become engaged in the developing and marketing of MedaCure’s health supplement
        that is believed to enhance and build-up the body’s natural immune system
        defenses in both humans and animals. Our first priority will be to establish
        new
        facilities for our corporate headquarters and to manufacture product. Management
        is seeking at least a 5,000 square foot facility that can be leased on a
        long-term basis. The facility must have a sterile environment with an assembly
        line capable of mass-producing and packaging the product. The facility will
        also
        handle shipping of product and receiving materials. We have not selected
        a final
        site, but we have identified the necessary manufacturing equipment and packaging
        machinery needed. We estimate that the cost to prepare the site for operation
        will be approximately $150,000.
 
 Contemporaneous
        with selecting the site for our operations, we will be creating a distribution
        network that will focus on initiating a collaboration and partnering program
        and
        developing business alliances designed to generate sales, applications and
        marketing opportunities. At present, we have not hired any sales or distribution
        personnel, but are in the process of initiating a search for qualified persons.
        We anticipate that during the next 12 months we will hire approximately 20
        persons, five for administrative duties, six for manufacturing and production,
        and nine for sales and marketing.
 
 We
        estimate that during the next 12 months we will need approximately $600,000
        to
        establish our manufacturing facility, establish a sales and distribution
        network, commence production of the MedaCure product and begin selling
        activities. We anticipate that the source of these funds will be from the
        private sale of securities and/or other financing activities conducted by
        our
        officers and directors. We anticipate that we will be able to raise
        approximately $2 million during the first half of 2007.
 
 **Inflation**
 
 In
        the
        opinion of management, inflation has not and will not have a material effect
        on
        our operations in the immediate future. Management will continue to monitor
        inflation and evaluate the possible future effects of inflation on our business
        and operations.
  14
  **Results
        of Operations**
 
 For
        the
        Period from Inception on April 25, 2006 Through December 31, 2006.
 
 Revenues
        from continuing operations for the year ended December 31, 2006 were $-0-.
        This
        lack of revenues was due primarily to the fact that our revenue stream
        pertaining to the Medacure subsidiary has not yet been sufficiently
        developed.
 
 Total
        operating expenses for the period ending December 31, 2006 were $108,133.
        These
        expenses are generally attributed to general and administrative expenses
        due to
        costs and professional fees associated with the due diligence associated
        with
        the Medacure acquisition and filing requirements during the year. We reported
        a
        net loss of $580,633 for the period ended December 31, 2006. The net loss
        was
        largely a result of the Company recognizing an impairment of assets in the
        amount of $472,500. This impairment relates to Medacure’s acquisition of certain
        research and development.
 
 **Liquidity
        and Capital Resources**
 
 At
        December 31, 2006, we had cash on hand of $29,443. We believe that current
        cash
        on hand is not sufficient to satisfy our cash requirements for the next twelve
        months, which we estimate to be approximately $600,000. Due to the fact that
        our
        limited operations have not generated cash flow sufficient to cover ongoing
        business expenses and/or we purchase additional equipment, we may have to
        rely
        on our directors, or on outside sources, to provide additional funds. However,
        we have no agreements with anyone to provide future funds to our Company.
        If our
        directors are unable to provide future funding, if the need arises, we may
        have
        to look at alternative sources of funding. We do not have any firm plans
        as to
        the source of this alternative funding and there is no assurance that such
        funds
        will be available or, that even if they are available, that they will be
        available on terms that will be acceptable to us. In the event we are unable
        to
        secure necessary future funding, we may have to curtail our business or cease
        operations completely.
 
 At
        December 31, 2006, we had total assets of $53,669 and stockholders' equity
        of
        $47,051.
 
 **Net
        Operating Loss**
 
 We
        have
        accumulated approximately $42,000 of net operating loss carryforwards as
        of
        December 31, 2006, which may be offset against taxable income and income
        taxes
        in future years. The use of these losses to reduce future income taxes will
        depend on the generation of sufficient taxable income prior to the expiration
        of
        the net operating loss carryforwards. The carry-forwards expire in the year
        2026. In the event of certain changes in control, there will be an annual
        limitation on the amount of net operating loss carryforwards which can be
        used.
        No tax benefit has been reported in the financial statements for the year
        ended
        December 31, 2006 because there is a 50% or greater chance that the carryforward
        will not be used. Accordingly, the potential tax benefit of the loss
        carryforward is offset by a valuation allowance of the same amount.
 
 **Forward
        Looking and Cautionary Statements**
 
 This
        report, including the sections entitled "Business," "Risk Factors" and
        "Management's Discussion and Analysis or Plan of Operations" contains
        forward-looking statements. These statements relate to future events or our
        future financial performance and involve known and unknown risks and
        uncertainties. These factors may cause our company's or our industry's actual
        results, levels of activity, performance or achievements to be materially
        different from those expressed or implied by the forward- looking statements.
        These risks and other factors include those listed under "Risk Factors" and
        elsewhere in this report. In some cases, you can identify forward-looking
        statements by terminology such as "may," "will" "should," "expects," "intends,"
        "plans," anticipates," "believes," "estimates," "predicts," "potential,"
        "continue," or the negative of these terms or other comparable
        terminology.
  15
  You
        should be aware that a variety of factors could cause actual results to differ
        materially from the anticipated results or other matters expressed in
        forward-looking statements. These risks and uncertainties, many of which
        are
        beyond our control, include:
 
 ·
                  the
                      sufficiency of existing capital resources and our ability to
                      raise
                      additional capital to fund cash requirements for future
                      operations;
 
 ·
                  uncertainties
                      following any successful acquisition or merger related to the
                      future rate
                      of growth of our business and acceptance of our products and/or
                      services;
 
 ·
                  volatility
                      of the stock market, particularly within the technology sector;
                      and
 
 ·
                  general
                      economic conditions.
 
 Although
        we believe the expectations reflected in these forward-looking statements
        are
        reasonable, such expectations cannot guarantee future results, levels of
        activity, performance or achievements.
 
 You
        are
        cautioned that any forward-looking statements are not guarantees of future
        performance and are subject to risks and uncertainties. Actual results may
        differ materially from those included within the forward-looking statements
        as a
        result of various factors. Cautionary statements in the risk factors section
        and
        elsewhere in this report identify important risks and uncertainties affecting
        our future, which could cause actual results to differ materially from the
        forward-looking statements made in this report.
 
 **Recent
        Accounting Pronouncements**
 
 In
        January 2003, the Financial Accounting Standards Board, or FASB, issued
        Interpretation No. 46 ("FIN 46"), Consolidation of Variable Interest Entities,
        which addresses the consolidation of business enterprises (variable interest
        entities), to which the usual condition of consolidation, a controlling
        financial interest, does not apply. FIN 46 requires an entity to assess its
        business relationships to determine if they are variable interest entities.
        As
        defined in FIN 46, variable interests are contractual, ownership or other
        interests in an entity that change with changes in the entity's net asset
        value.
        Variable interests in an entity may arise from financial instruments, service
        contracts, guarantees, leases or other arrangements with the variable interest
        entity. An entity that will absorb a majority of the variable interest entity's
        expected losses or expected residual returns, as defined in FIN 46, is
        considered the primary beneficiary of the variable interest entity. The primary
        beneficiary must include the variable interest entity's assets, liabilities
        and
        results of operations in its consolidated financial statements. FIN 46 is
        immediately effective for all variable interest entities created after January
        31, 2003. For variable interest entities created prior to this date, the
        provisions of FIN 46 were originally required to be applied no later than
        our
        first quarter of Fiscal 2004. On October 8, 2003, the FASB issued FASB Staff
        Position (FSP) FIN 46-6, Effective Date of FASB Interpretation No. 46,
        Consolidation of Variable Interest Entities. The FSP provides a limited deferral
        (until the end of our second quarter of 2004) of the effective date of FIN
        46
        for certain interests of a public entity in a variable interest entity or
        a
        potential variable interest entity. FIN 46 did not have a material impact
        on our
        financial statements for the year ended December 31, 2006.
 
 In
        April
        2003, the FASB issued Statement of Financial Accounting Standards (SFAS)
        SFAS
        No. 149, Amendment of Statement 133 on Derivative Instruments and Hedging
        Activities. SFAS No. 149 amends and clarifies accounting for derivative
        instruments, including certain derivative instruments embedded in other
        contracts, and for hedging activities under SFAS No. 133. In particular,
        this
        Statement clarifies under what circumstances a contract with an initial net
        investment meets the characteristic of a derivative and when a derivative
        contains a financing component that warrants special reporting in the statement
        of cash flows. We adopted this standard for contracts entered into or modified
        after June 30, 2003. The adoption of SFAS No. 149 did not have a material
        impact
        on our consolidated results of operations or financial position.
  16
  In
        May
        2003, the FASB issued SFAS No. 150, Accounting for Certain Financial Instruments
        with Characteristics of both Liabilities and Equity. This Statement requires
        certain financial instruments that embody obligations of the issuer and have
        characteristics of both liabilities and equity to be classified as liabilities.
        We adopted this standard for financial instruments entered into or modified
        after May 31, 2003. The adoption of SFAS No. 150 did not have a material
        impact
        on our consolidated results of operations or financial position.
 
 On
        December 16, 2004 the FASB issued SFAS No. 123(R), Share-Based Payment, which
        is
        an amendment to SFAS No. 123, Accounting for Stock-Based Compensation. This
        new
        standard eliminates the ability to account for share-based compensation
        transactions using Accounting Principles Board ("APB") Opinion No. 25,
        Accounting for Stock Issued to Employees, and generally requires such
        transactions to be accounted for using a fair-value-based method and the
        resulting cost recognized in our financial statements. This new standard
        is
        effective for awards that are granted, modified or settled in cash in interim
        and annual periods beginning after June 15, 2005. In addition, this new standard
        will apply to unvested options granted prior to the effective date. We will
        adopt this new standard effective for the fourth fiscal quarter of 2005,
        and
        have not yet determined what impact this standard will have on our financial
        position or results of operations.
 
 In
        November 2004, the FASB issued SFAS No. 151, Inventory Costs - an amendment
        of
        ARB No. 43, Chapter 4. This Statement amends the guidance in ARB No. 43,
        Chapter
        4, "Inventory Pricing," to clarify the accounting for abnormal amounts of
        idle
        facility expense, freight, handling costs, and wasted material (spoilage).
        Paragraph 5 of ARB 43, Chapter 4, previously stated that ". . . under some
        circumstances, items such as idle facility expense, excessive spoilage, double
        freight, and rehandling costs may be so abnormal as to require treatment
        as
        current period charges. . . ." This Statement requires that those items be
        recognized as current-period charges regardless of whether they meet the
        criterion of "so abnormal." In addition, this Statement requires that allocation
        of fixed production overheads to the costs of conversion be based on the
        normal
        capacity of the production facilities. This statement is effective for inventory
        costs incurred during fiscal years beginning after June 15, 2005. Management
        does not believe the adoption of this Statement will have any immediate material
        impact on the Company.
 
 In
        December 2004, the FASB issued SFAS No. 152, Accounting for Real Estate
        Time-sharing Transactions, which amends FASB statement No. 66, Accounting
        for
        Sales of Real Estate, to reference the financial accounting and reporting
        guidance for real estate time-sharing transactions that is provided in AICPA
        Statement of Position (SOP) 04-2, Accounting for Real Estate Time-Sharing
        Transactions. This statement also amends FASB Statement No. 67, Accounting
        for
        Costs and Initial Rental Operations of Real Estate Projects, to state that
        the
        guidance for (a) incidental operations and (b) costs incurred to sell real
        estate projects does not apply to real estate time-sharing transactions.
        The
        accounting for those operations and costs is subject to the guidance in SOP
        04-2. This Statement is effective for financial statements for fiscal years
        beginning after June 15, 2005. Management believes the adoption of this
        Statement will have no impact on the financial statements of the
        Company.
 
 In
        December 2004, the FASB issued SFAS No.153, Exchange of Nonmonetary Assets.
        This
        Statement addresses the measurement of exchanges of nonmonetary assets. The
        guidance in APB Opinion No. 29, Accounting for Nonmonetary Transactions,
        is
        based on the principle that exchanges of nonmonetary assets should be measured
        based on the fair value of the assets exchanged. The guidance in that Opinion,
        however, included certain exceptions to that principle. This Statement amends
        Opinion 29 to eliminate the exception for nonmonetary exchanges of similar
        productive assets and replaces it with a general exception for exchanges
        of
        nonmonetary assets that do not have commercial substance. A nonmonetrary
        exchange has commercial substance if the future cash flows of the entity
        are
        expected to change significantly as a result of the exchange. This Statement
        is
        effective for financial statements for fiscal years beginning after June
        15,
        2005. Earlier application is permitted for nonmonetary asset exchanges incurred
        during fiscal years beginning after the date of this statement is issued.
        Management believes the adoption of this Statement will have no impact on
        the
        financial statements of the Company.
  17
  **Item
        7. Financial Statements**
 
 Financial
        statements for the fiscal years ended December 31, 2006 and 2005 have been
        examined to the extent indicated in their reports by Moore & Associates,
        Chartered, independent certified public accountants and have been prepared
        in
        accordance with generally accepted accounting principles and pursuant to
        Regulation S-B as promulgated by the SEC. The aforementioned financial
        statements are included below.
  **CURATECH
        INDUSTRIES, INC.**
 **(Formerly
        Jump’n Jax, Inc.)**
 
 **FINANCIAL
        STATEMENTS**
 
 December
        31, 2006
  18
   **MOORE
        & ASSOCIATES, CHARTERED**
 ** *ACCOUNTANTS
        AND ADVISORS*
 *PCAOB
        REGISTERED*
 
 REPORT
        OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
  To
        the
        Board of Directors
 Curatech
        Indstries, Inc.
 (A
        Development Stage Company)
 Minden,
        NV
 
 We
        have
        audited the accompanying balance sheet of Curatech Industries, Inc. (a
        development stage company) as of December 31, 2006, and the related statements
        of operations, stockholders’ equity (deficit) and cash flows for the period from
        inception on April 25, 2006 through December 31, 2006. These financial
        statements are the responsibility of the Company’s management. Our
        responsibility is to express an opinion on these financial statements based
        on
        our audits.
 
 We
        conducted our audits in accordance with standards of the Public Company
        Accounting Oversight Board (United States). Those standards require that
        we plan
        and perform the audits to obtain reasonable assurance about whether the
        financial statements are free of material misstatement. An audit includes
        examining, on a test basis, evidence supporting the amounts and disclosures
        in
        the financial statements. An audit also includes assessing the accounting
        principles used and significant estimates made by management, as well as
        evaluating the overall financial statement presentation. We believe that
        our
        audits provide a reasonable basis for our opinion.
 
 In
        our
        opinion, the financial statements referred to above present fairly, in all
        material respects, the financial position of Curatech Industries, Inc. (a
        development stage company) **** as
        of
        December 31, 2006 and the results of its operations and its cash flows for
        the
        period from inception on April 25, 2006 through December 31, 2006, in conformity
        with accounting principles generally accepted in the United States of
        America.
 
 The
        accompanying financial statements have been prepared assuming that the Company
        will continue as a going concern. As discussed in Note 2 to the financial
        statements, the Company’s lack of significant operations and minimal current
        assets raises substantial doubt about its ability to continue as a going
        concern. Management’s plans concerning these matters are also described in Note
        2. The financial statements do not include any adjustments that might result
        from the outcome of this uncertainty.
 
 As
        discussed in Note 1 to the financial statements, the audited financial
        statements have been restated to correct an accounting error with respect
        to the
        Company’s reverse-acquisition of Medacure in October, 2006.
 
 /s/Moore
        & Associates Chartered
 Moore
        & Associates Chartered
 Las
        Vegas, Nevada
 September
        4, 2007
  *2675
        S. Jones Blvd. Suite 109, Las Vegas, NV 89146 (702) 253-7511 Fax (702)
        253-7501*
  19
  **CURATECH
                    INDUSTRIES, INC.**(A
                    Development Stage Company)Balance
                    Sheet
  December
                    31,2006ASSETSCURRENT
                    ASSETSCash
                
                $
                29,443Note
                    receivable - related party
                
                
                17,415Total
                    Current Assets
                
                
                46,858FIXED
                    ASSETS, Net
                
                
                6,811TOTAL
                    ASSETS
                
                $
                53,669LIABILITIES
                    AND STOCKHOLDERS' EQUITY (DEFICIT)CURRENT
                    LIABILITIESAccounts
                    payable
                
                $
                1,330Notes
                    payable - related party
                
                
                5,288Total
                    Current Liabilities
                
                
                6,618TOTAL
                    LIABILITIES
                
                
                6,618STOCKHOLDERS'
                    EQUITY (DEFICIT)Common
                    stock: 25,000,000 shares authorized;$0.001
                    par value; 15,572,647 shares issued andoutstanding
                
                
                15,573Additional
                    paid-in capital
                
                
                667,111Stock
                    subscriptions receivable
                
                
                (55,000
                )Deficit
                    accumulated during the development stage
                
                
                (580,633
                )Total
                    Stockholders' Equity (Deficit)
                
                
                47,051TOTAL
                    LIABILITIES AND STOCKHOLDERS'EQUITY
                    (DEFICIT)
                
                $
                53,669
  The
                    accompanying notes are an integral part of these financial
                    statements.
  20
  **CURATECH
                    INDUSTRIES, INC.**(A
                    Development Stage Company)Statements
                    of Operations
  From
                    Inception of the Development Stage on April 25, 2006 through
                    December
                    31,2006REVENUES
                
                $
                -OPERATING
                    EXPENSESGeneral
                    and administrative
                
                
                108,133Total
                    Operating Expenses
                
                
                108,133LOSS
                    FROM OPERATIONS
                
                
                (108,133
                )OTHER
                    EXPENSESImpairment
                    of assets
                
                
                (472,500
                )Total
                    Other Expenses
                
                
                (472,500
                )NET
                    LOSS
                
                $
                (580,633
                )BASIC
                    LOSS PER SHARE
                
                $
                (0.06
                )WEIGHTED
                    AVERAGE NUMBER OFSHARES
                    OUTSTANDING
                
                
                9,655,041
  The
                    accompanying notes are an integral part of these financial
                    statements.
  21
  **CURATECH
                    INDUSTRIES, INC.**(A
                    Development Stage Company)Statements
                    of Stockholders' Equity (Deficit)
 DeficitAccumulatedAdditional
                  
                  Stock
                  
                  During
                      theCommon
                      Stock
                  
                  Paid-In
                  
                  Subscription
                  
                  DevelopmentShares
                  
                  Amount
                  
                  Capital
                  
                  Receivable
                  
                  StageBalance,
                      at inception on April 25, 2006
                  
                  
                  -
                  
                  $
                  -
                  
                  $
                  -
                  
                  $
                  -
                  
                  $
                  -Common
                      shares issued for cash at $0.001 per share
                  
                  
                  11,495,633
                  
                  
                  11,496
                  
                  
                  (796
                  )
                  
                  -
                  
                  
                  -Common
                      shares issued pursuant to Asset Purchase Agreement at $0.60
                      per
                      share
                  
                  
                  578,000
                  
                  
                  578
                  
                  
                  321,922
                  
                  
                  -
                  
                  
                  -Common
                      shares issued for cash at $0.60 per share
                  
                  
                  268,606
                  
                  
                  269
                  
                  
                  149,731
                  
                  
                  (55,000
                  )
                  
                  -Recapitalization
                      pursuant to reverse merger
                  
                  
                  3,230,408
                  
                  
                  3,230
                  
                  
                  196,254
                  
                  
                  -
                  
                  
                  -Increase
                      in stock subscriptions receivable
                  
                  
                  -
                  
                  
                  -
                  
                  
                  -
                  
                  
                  -
                  
                  
                  -Net
                      loss for the period from inception on April 25, 2006 through
                      December 31,
                      2006
                  
                  
                  -
                  
                  
                  -
                  
                  
                  -
                  
                  
                  -
                  
                  
                  (580,633
                  )15,572,647
                  
                  $
                  15,573
                  
                  $
                  667,111
                  
                  
                  (55,000
                  )
                  $
                  (580,633
                  )
  The
            accompanying notes are an integral part of these financial
            statements.
  22
  **CURATECH
                    INDUSTRIES, INC.**(A
                    Development Stage Company)Statements
                    of Cash Flows
  From
                    Inception of the Development Stage on April 25, 2006 Through
                    December 31,
                    2006CASH
                    FLOWS FROM OPERATING ACTIVITIESNet
                    loss
                
                $
                (580,633
                )Adjustments
                    to reconcile net loss tonet
                    cash used by operating activities:Impairment
                    of investments
                
                
                472,500Increase
                    in accounts payable
                
                
                1,330Net
                    Cash Used by Operating Activities
                
                
                (106,803
                )CASH
                    FLOWS FROM INVESTING ACTIVITIESCash
                    paid for IRT investment
                
                
                (150,000
                )Net
                    Cash Used by Investing Activities
                
                
                (150,000
                )CASH
                    FLOWS FROM FINANCING ACTIVITIESCommon
                    stock issued for cash
                
                
                160,700Cash
                    received in acquisition
                
                
                137,673Cash
                    received for note payable
                
                
                5,288Cash
                    paid on note payable, related party
                
                
                (17,415
                )Net
                    Cash Provided by Financing Activities
                
                
                286,246NET
                    INCREASE IN CASH
                
                
                29,443CASH
                    AT BEGINNING OF PERIOD
                
                
                -CASH
                    AT END OF PERIOD
                
                $
                29,443SUPPLEMENTAL
                    DISCLOSURES OFCASH
                    FLOW INFORMATIONCASH
                    PAID FOR:Interest
                
                $
                -Taxes
                
                $
                -NON-CASH
                    FINANCING ACTIVITIESCommon
                    stock issued for fixed assets
                
                $
                322,500
 The
            accompanying notes are an integral part of these financial
            statements.
  23
  **CURATECH
          INDUSTRIES, INC.**
 (A
          Development Stage Company)
 Notes
          to
          the Financial Statements (Continued)
 December
          31, 2006
  NOTE
          1
          -  RESTATED
          FINANCIAL STATEMENTS
 
 The
          historical financial statements of Curatech Industries, Inc. (“Curatech”) as of
          December 31, 2006 attached hereto have been restated so as to correctly
          account
          for the Company’s acquisition transaction with MedaCure International, Inc.
          (“MedaCure”) on October 26, 2006 (see Note 6). Subsequent to the completion of
          the audit of the Company’s December 31, 2006 financial statements, the Company’s
          management determined that the financial statements had incorrectly accounted
          for the transaction. The transaction was originally accounted for as a
          purchase
          arrangement, with Curatech purchasing MedaCure, and Curatech continuing
          as the
          accounting acquirer. The historical financial statements attached hereto
          have
          been restated so as to account for the transaction as a reverse-acquisition,
          with MedaCure presented as the accounting acquirer.
 
 NOTE
          2
          -  SUMMARY
          OF SIGNIFICANT ACCOUNTING POLICIES
 
 a.
          Organization
 
 Curatech
          Industries, Inc. (the Company) was incorporated as a Utah Corporation in
          March
          2000 under the name Jump’n Jax, Inc.. The Company was in the business of
          recreation equipment rentals until December 31, 2005, at which time the
          Company
          ceased equipment rental activities. In October 2006, the Company consummated
          an
          agreement to acquire Medacure International, Inc., a Nevada corporation.
          Pursuant to this Agreement, the Company changed its state of domicile from
          Utah
          to Nevada, and changed its corporate name to Curatech Industries, Inc.
          The
          Company is currently in the business of developing and marketing proprietary
          health supplements.
 
 b.
          Accounting Method
 
 The
          financial statements are prepared using the accrual method of accounting.
          The
          Company has elected a calendar year-end.
 
 c.
          Estimates
 
 The
          preparation of financial statements in conformity with accounting principles
          generally accepted in the United States of America requires management
          to make
          estimates and assumptions that affect the reported amounts of assets and
          liabilities and disclosure of contingent assets and liabilities at the
          date of
          the financial statements and the reported amounts of revenues and expenses
          during the reporting period. Actual results could differ from those
          estimates.
 
 d.
          Revenue Recognition
 
 The
          Company earned zero revenues during the period ended December 31, 2006.
          Appropriate revenue recognition principles will be established once
          revenue-generating operations commence.
 
 24
  **CURATECH
            INDUSTRIES, INC.**
 (A
            Development Stage Company)
 Notes
            to
            the Financial Statements (Continued)
 December
            31, 2006
  NOTE
            2
            -  SUMMARY
            OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
 
 b.
          Provision for Taxes
 
 Deferred
          taxes are provided on a liability method whereby deferred tax assets are
          recognized for deductible temporary differences and operating loss and
          tax
          credit carryforwards and deferred tax liabilities are recognized for taxable
          temporary differences. Temporary differences are the differences between
          the
          reported amounts of assets and liabilities and their tax bases. Deferred
          tax
          assets are reduced by a valuation allowance when, in the opinion of management,
          it is more likely than not that some portion or all of the deferred tax
          assets
          will not be realized. Deferred tax assets and liabilities are adjusted
          for the
          effects of changes in tax laws and rates on the date of enactment.
 
 Net
          deferred tax assets consist of the following components as of December
          31,
          2006:
 2006Deferred
                      tax assets:NOL
                      Carryover
                  
                  $
                  42,172Deferred
                      tax liabilities:
                  
                  
                  -Valuation
                      allowance
                  
                  
                  (42,172
                  )Net
                      deferred tax asset
                  
                  $
                  -
 
 The
          income tax provision differs from the amount of income tax determined by
          applying the U.S. federal and state income tax rates of 39% to pretax income
          from continuing operations for the period ended December 31, 2006 due to
          the
          following:
 2006Book
                      income
                  
                  $
                  226,447Impairment
                      of assets
                  
                  
                  (184,275
                  )Valuation
                      allowance
                  
                  $
                  42,172
  NOTE
          3
          -  GOING
          CONCERN
 
 The
          Company's financial statements are prepared using accounting principles
          generally accepted in the United States of America applicable to a going
          concern
          which contemplates the realization of assets and liquidation of liabilities
          in
          the normal course of business. The Company has not established revenues
          sufficient to cover its operating costs and allow it to continue as a going
          concern. Management intends to increase operations through expanding its
          operations into other locals, in the interim, management and primary
          shareholders are committed to meeting the Company minimal operating
          expenses.
  25
 **CURATECH
            INDUSTRIES, INC.**
 (A
            Development Stage Company)
 Notes
            to
            the Financial Statements (Continued)
 December
            31, 2006
  NOTE
          4
          -  COMMON
          STOCK TRANSACTIONS
 
 On
          April
          28, 2006, the Company issued an aggregate of 11,495,633 shares of common
          stock
          to various individuals, each of whom was an officer and/or director of
          the
          Company on the date of issuance, in exchange for an aggregate of $10,700
          in
          cash.
 
 On
          May
          12, 2006, the Company issued an aggregate of 578,000 shares of common stock
          to
          two unrelated individuals, as partial payment for Immune Response Therapy
          assets
          (see Note 4).
 
 On
          May
          15, 2006, the Company issued 268,606 shares of common stock to an unrelated
          third party in exchange for $150,000 in cash. Of this amount, $55,000 remained
          uncollected as of December 31, 2006, and has been recorded as stock
          subscriptions receivable.
 
 NOTE
          5 -
          RELATED PARTY TRANSACTIONS
 
 During
          the year ended December 31, 2006 the Company has at various times made
          temporary
          loans to the Company’s Chief Executive Officer. The outstanding balance of these
          loans at December 31, 2006, including accrued interest, is $17,415.
 
 NOTE
          6 -
          AGREEMENT AND PLAN OF MERGER
 
 On
          October 26, 2006, the Company entered into an Acquisition Agreement with
          Jump’n
          Jax, Inc. (“Jump’n Jax”). The acquisition was consummated pursuant to an
          agreement entered into on June 22, 2006, whereby the Company agreed to
          merge
          into Jump’n Jax’s newly created, wholly-owned subsidiary, CuraTech Acquisitions,
          Inc., with the Company being the surviving entity as Jump’n Jax’s wholly owned
          operating subsidiary.
 
 Prior
          to
          completion of the acquisition on October 4, 2006, the Jump’n Jax completed a
          forward stock split, on a four shares for one share basis. In addition,
          Jump’n
          Jax changed its corporate name to CuraTech Industries, Inc. As a result
          of the
          forward stock split, Jump’n Jax’s outstanding shares of common stock increased
          from 807,602 shares to 3,230,408 shares. The Company also changed its corporate
          domicile from the State of Utah to Nevada. Additionally, per the terms
          of the
          Merger Agreement the Jump’n Jax issued an aggregate of 12,342,239 shares of its
          common stock, post-split, to the stockholders of the Company. Also, the
          Company
          added three new directors, each nominated by MedaCure, to its Board of
          Directors. Upon completion of the Acquisition, approximately 58.9% of the
          Company’s common stock is beneficially owned together by the Dastrup family.
          Accordingly, this group has the capability to substantially control the
          vote on
          all significant matters pertaining to the Company without the approval
          of
          shareholders.
 
 The
          Company accounted for this transaction as a reverse-acquisition, with MedaCure
          presented as the accounting acquirer. Therefore, the historical financial
          statements presented herein reflect only those of MedaCure, the accounting
          acquirer, since its inception on April 25, 2006. The reverse-acquisition
          is
          presented as a recapitalization of Medacure. Accordingly, the historical
          stockholders’ equity (deficit) of MedaCure prior to the acquisition transaction
          has been retroactively restated pursuant to SFAS 141.
 
 From
          the
          consummation of the Merger Agreement, the Company has begun the development
          and
          bringing to market a certain health supplement that is intended to enhance
          and
          build-up the body’s natural immune system defenses. The Company intends to
          commence commercial marketing of its supplement in the near future primarily
          outside the U.S. Initial marketing in the U.S. will primarily be to the
          veterinarian market for use in treating animals. The Company also intends
          to
          initiate a collaboration and partnering program that will focus on developing
          business alliances designed to generate sales, applications and marketing
          opportunities.
  26
 **CURATECH
            INDUSTRIES, INC.**
 (A
            Development Stage Company)
 Notes
            to
            the Financial Statements (Continued)
 December
            31, 2006
 
 NOTE
          7 -  ASSET
          PURCHASE AGREEMENT
 
 On
          May
          15, 2006 the Company entered into an Asset Purchase Agreement whereby the
          Company acquired certain exclusive proprietary Immune Response Therapy
          (“IRT”)
          products and technologies from Dr. William and Freida Stacey, in exchange
          for
          $150,000 in cash and 537,500 shares of the Company’s common stock. The shares in
          this transaction have been valued at $0.60 per share, or $322,500, bringing
          the
          total value of the consideration paid by the Company for the IRT assets
          to
          $472,500.
 
 To
          the
          date of these financial statements, the Company has yet to realize significant
          revenues from the utilization of the IRT assets. The Company’s management
          continues to focus its business strategy on the utilization of the IRT
          assets.
          However, due to the fact that no significant revenues have been generated
          from
          the IRT assets, the Company has fully impaired the IRT assets as of May
          31,
          2006. Accordingly, an asset impairment expense of $472,500 for the period
          ended
          May 31, 2006.
  27
 
 **Item
        8. Changes in and Disagreements with Accountants on Accounting and** **Financial
        Disclosure**
 
 (a)
        On
        March 31, 2006, HJ & Associates, LLC was terminated as the certifying
        accountant for the Company (the "Registrant").
 
 HJ
&
        Associates, LLC has served from the inception of the Company as the certifying
        accountant for the Company’s financial statements. From the date on which HJ
& Associates, LLC was engaged until the date HJ & Associates, LLC was
        terminated, there were no disagreements with HJ & Associates, LLC on any
        matter of accounting principles or practices, financial statement disclosure,
        or
        auditing scope or procedure, which disagreements, if not resolved to the
        satisfaction of HJ & Associates, LLC would have caused HJ & Associates,
        LLC to make reference to the subject matter of the disagreements in connection
        with any reports it would have issued, and there were no "reportable events"
        as
        that term is defined in Item 304(a)(1)(iv) of Regulation S-B.
 
 (b)
        On
        March 29, 2006, the Company entered into an engagement letter with Moore
&
Associates, Chartered **** to
        assume
        the role of its new certifying accountant. Moore & Associates,
        Chartered **** has
        been
        asked to audit the year ended December 31, 2006. During the two most recent
        fiscal years and the subsequent interim periods prior to the engagement of
        Moore
& Associates, Chartered, the Company did not consult with Moore &
Associates, Chartered, with regard to:
 
 (i)
        the
        application of accounting principles to a specified transaction, either
        completed or proposed; or the type of audit opinion that might be rendered
        on
        the Company's financial statements; or
 
 (ii)
        any
        matter that was either the subject of a disagreement or a reportable event
        (as
        described in Item 304(a)(1)(iv) of Regulation S-B).
 
 The
        engagement of the new principal auditor was recommended and approved by the
        Company’s Board of Directors.
 
 **Item
        8A. Controls and Procedures**
 
 As
        of the
        end of the period covered by this report, we carried out an evaluation, under
        the supervision and with the participation of management, including our chief
        executive officer and chief financial officer, of the effectiveness of the
        design and operation of our disclosure controls and procedures as defined
        in
        Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934. Based
        upon
        that evaluation, our chief executive officer and chief financial officer
        concluded that our disclosure controls and procedures are effective to cause
        the
        material information required to be disclosed by us in the reports that we
        file
        or submit under the Exchange Act to be recorded, processed, summarized and
        reported within the time periods specified in the SEC's rules and forms.
        There
        have been no significant changes in our internal controls or in other factors
        which could significantly affect internal controls subsequent to the date
        we
        carried out our evaluation.
 
 **Item
        8B. Other Information**
 
 Not
        applicable.
  28
  **PART
        III**
  **Item
        9. Directors, Executive Officers, Promoters and Control Persons;** **Compliance
        with Section 16(a) of the Exchange Act**
 
 **Identification
        of directors and executive officers**
 
 Upon
        completion of the MedaCure acquisition, our former President, Lane S. Clissold
        submitted his resignation as a director and President. Steven D. Moulton
        remained on the board of directors until January 4, 2007, when he resigned.
        In
        accordance with the provisions of the acquisition, MedaCure appointed three
        new
        directors, Lincoln Dastrup, Linda L. Dastrup and Jarom Dastrup, to serve
        on the
        board of directors. Lincoln Dastrup was elected CEO. Jarom Dastrup was elected
        Executive Vice President and Secretary, and Linda L. Dastrup was elected
        Treasurer. The following persons currently serve as directors and executive
        officers.
  **Name**
              
              **Age**
              
              **Position**Lincoln
                  Dastrup
              
              52
              
              CEO,
                  CFO and DirectorJarom
                  Dastrup
              
              27
              
              Executive
                  Vice President, Secretary and DirectorLinda
                  L. Dastrup
              
              48
              
              Treasurer
                  and Director
  All
        directors hold office until the next annual meeting of stockholders and until
        their successors have been duly elected and qualified. There are no agreements
        with respect to the election of directors. We have not compensated directors
        for
        service on the board of directors or any committee thereof, but directors
        are
        entitled to be reimbursed for expenses incurred for attendance at meetings
        of
        the board and any committee of the board. Officers are appointed annually
        by the
        board and each executive officer serves at the discretion of the board. We
        do
        not have any standing committees.
 
 Currently,
        there is no arrangement, agreement or understanding between management and
        non-management stockholders under which non-management stockholders may directly
        or indirectly participate in or influence the management of our affairs.
        Present
        management openly accepts and appreciates any input or suggestions from
        stockholders. However, the board is elected by the stockholders and the
        stockholders have the ultimate say in who represents them on the board. There
        are no agreements or understandings for any officer or director to resign
        at the
        request of another person and none of the current offers or directors are
        acting
        on behalf of, or will act at the direction of any other person.
 
 The
        business experience of each of the persons listed above during the past five
        years is as follows:
 
 ***Lincoln
        Dastrup.*** Mr.
        Dastrup has served as a director and as CEO and CFO of the Company since
        October
        2006. Mr. Dastrup has over 26 years of experience in investment banking,
        corporate development, management, marketing and manufacturing with public
        companies. Since 1995, he has been semi-retired and primarily manages his
        personal investments. In 1989, Mr. Dastrup co-founded CIMETRIX Incorporated,
        an
        international robotics firm. Mr. Dastrup served as the President and CEO
        of
        CIMETRIX until 1995. In 1986 Mr. Dastrup founded Corporate Funding, a venture
        capital firm. Prior to that Mr. Dastrup was the founder, President and CEO
        of
        Barron, Marshal, & Kaman, a New York based investment banking firm, and
        members of the New York Stock Exchange. In 1979 Mr. Dastrup was a co-founder
        of
        Universal Fashions Originals, a company engaged in the business of clothing
        manufacturing and design. In 1980, Universal Fashions merged with an
        over-the-counter public company. After the merger, Mr. Dastrup served as
        a
        director, executive vice-president and president of its wholly-owned subsidiary,
        Classic Covers, Inc. Since 1980, Mr. Dastrup has participated in over 14
        mergers
        and acquisitions and has financed seven companies.
  29
  ***Linda
        L. Dastrup*** .
        Mrs.
        Dastrup has served as a director and as Treasurer of the Company since October
        2006. Mrs. Dastrup has over 20 years of experience in corporate development,
        management and manufacturing with public companies. Since 1995, she has been
        semi-retired and primarily manages her personal investments. In 1989, Mrs.
        Dastrup co-founder CIMETRIX Incorporated, an International robotics firm.
        Mrs.
        Dastrup was a key contributor to the original buy/sale and royalty agreement
        of
        CIMETRIX Incorporated. She served as an executive officer of CIMETRIX for
        over 5
        years. Prior to that Mrs. Dastrup was a Director and Treasurer of Barron,
        Marshal, & Kaman, a New York based Investment Banking firm, and members of
        the New York Stock Exchange. In 1979 Mrs. Dastrup was a co-founder of Universal
        Fashions Originals, a Company engaged in the business of clothing manufacturing
        and design. In 1980 Universal Fashions merged with an over-the-counter public
        Company. Mrs. Dastrup’s responsibilities included that of all manufacturing and
        design. Mrs. Dastrup is the wife of Lincoln Dastrup.
 
 ***Jarom
        L. Dastrup*** **.** Mr.
        Dastrup has servied as a director and as Executive Vice President and Secretary
        of the Company since October 2006. Mr. Dastrup has over 5 years of experience
        in
        corporate development, and administration. Since 2005, Mr. Dastrup has been
        a
        private money advisor and manager. In 2006 Mr. Dastrup was co-founder and
        Manager of Vastmann Investment Partners, LLC, a private equity fund. Currently
        Mr. Dastrup is responsible for all client relations, client accounts, client
        investments, and all company finances. Prior to that Mr. Dastrup managed
        a
        portfolio of stocks, options, and futures. In 2002 Mr. Dastrup was a partner
        in
        and managed The Iceberg Drive-In, a Utah based fast food restaurant. Mr.
        Dastrup
        graduated from Utah Valley State College where he received his Bachelor Degree
        in Business Management. Mr. Dastrup is the son of Lincoln and Linda
        Dastrup.
 
 **Significant
        employees**
 
 Curatech
        Industries, Inc. and its subsidiary have no present employees who are expected
        to make a significant contribution to the Company’s business other than the
        Company’s current officers and directors. It is expected that current members of
        management will be the only persons whose activities will be material to
        the
        Company = s
        operations.
 
 **Family
        relationships**
 
 There
        are
        no family relationships between any directors or executive officers of the
        Company and/or the officers, directors or managers of its subsidiary, MedaCure,
        either by blood or by marriage, except for the following: Lincoln Dastrup
        and
        Linda L. Dastrup are husband and wife. Jarom Dastrup is their son.
 
 **Involvement
        in certain legal proceedings**
 
 During
        the past five years, no present or former director, person nominated to become
        a
        director, executive officer, promoter or control person of the
        Company:
 
 (1)
        was a
        general partner or executive officer of any business which filed a petition
        in
        bankruptcy or against which any bankruptcy petition was filed, either at
        the
        time of the bankruptcy or two years prior to that time;
  30
  (2)
        was
        convicted in a criminal proceeding or named subject to a pending criminal
        proceeding (excluding traffic violations and other minor offenses);
 
 (3)
        was
        subject to any order, judgment or decree, not subsequently reversed, suspended
        or vacated, of any court of competent jurisdiction, permanently or temporarily
        enjoining, barring, suspending or otherwise limiting his involvement in any
        type
        of business, securities or banking activities; or
 
 (4)
        was
        found by a court of competent jurisdiction (in a civil action), the Securities
        and Exchange Commission or the Commodity Futures Trading Commission to have
        violated a federal or state securities or commodities law, and the judgment
        has
        not been reversed, suspended or vacated.
 
 **Section
        16(a) beneficial ownership reporting compliance**
 
 Based
        solely upon a review of Forms 3 and 4 furnished to the Company under Rule
        16a-3(d) during its most recent fiscal year, the Company knows of no person
        who
        was a director, officer, beneficial owner of more than ten percent of any
        class
        of equity securities of the Company registered pursuant to Section 12
        ("Reporting Person") that failed to file on a timely basis any reports required
        to be furnished pursuant to Section 16(a) during the most recent fiscal year,
        except for the following:
 
 (1)
        On
        November 3, 2006, Steven Moulton filed a Form 4 report disclosing stock sales
        which he made on October 30, October 31 and November 1. The report should
        have
        been filed within two business days of each sale.
 
 (2)
        On
        December 5, 2006, the Dastrup Family Trust filed a Form 3 report that should
        have been filed within ten days of June 16, 2006.
 
 (3)
        On
        December 5, 2006, the Dastrup Family Trust filed a Form 4 report to report
        an
        acquisition of shares that occurred on October 26, 2006. The report should
        have
        been filed within two business days of October 26, 2006.
 
 (4)
        On
        December 5, 2006, Linda L. Dastrup filed a Form 3 report that should have
        been
        filed within ten days of October 26, 2006.
 
 (5)
        On
        December 5, 2006, Jarom L. Dastrup filed a Form 3 report that should have
        been
        filed within ten days of October 26, 2006.
 
 (6)
        On
        December 5, 2006, Lincoln M. Dastrup filed a Form 3 report that should have
        been
        filed within ten days of October 26, 2006.
  **Item
        10. Executive Compensation**
 
 **Cash
        compensation**
 
 The
        following table sets forth the aggregate compensation paid by the Company
        and/or
        its subsidiaries to the Company’s Chief Executive Officer and to any other
        officer, director or employee who received $100,000 or more during any of
        the
        last three fiscal years:
  **SUMMARY
                        COMPENSATION TABLE**Long
                        Term CompensationAnnual
                        Compensation Awards
                    
                    Payouts(a)
                    
                    (b)
                    
                    (c)
                    
                    (d)
                    
                    (e)
                    
                    (f)
                    
                    (g)
                    
                    (h)
                    
                    (i)Secur-ities
                    
                    
                    
                    AllYear
                        or
                    
                    
                    
                    
                    
                    Other
                    
                    Rest-
                    
                    Under-
                    
                    LTIP
                    
                    OtherName
                      and
                    
                    Period
                    
                    Salary
                    
                    Bonus
                    
                    Annual
                    
                    ricted
                    
                    lying
                    
                    Pay-
                    
                    Compen-Principal
                            Position
                    
                    Ended
                    
                    ($)
                    
                    ($)
                    
                    Compen-
                    
                    Stock
                    
                    Options
                    
                    outs
                    
                    sationLincolnDastrup(1)
                    
                    
                    12/31/06
                    
                    $
                    17,800
                    
                    
                    0
                    
                    
                    0
                    
                    
                    0
                    
                    
                    0
                    
                    
                    0
                    
                    
                    0LaneClissold(1)
                    
                    
                    12/31/06
                    
                    $
                    0
                    
                    
                    0
                    
                    
                    0
                    
                    
                    0
                    
                    
                    0
                    
                    
                    0
                    
                    
                    0LaneClissold
                    
                    
                    12/31/05
                    
                    $
                    0
                    
                    
                    0
                    
                    
                    0
                    
                    
                    0
                    
                    
                    0
                    
                    
                    0
                    
                    
                    0LaneClissold
                    
                    
                    12/31/04
                    
                    $
                    0
                    
                    
                    0
                    
                    
                    0
                    
                    
                    0
                    
                    
                    0
                    
                    
                    0
                    
                    
                    0
  
 (1)
        Lane
        Clissold served as CEO until October 2006 when Lincoln Dastrup became
        CEO.
  31
 
 Except
        as
        described above, no cash compensation, deferred compensation or long-term
        incentive plan awards were issued or granted to the Company = s
        management during the fiscal years ended December 31, 2006 and 2005. Except
        as
        described above, no other officers or directors were paid any salaries or
        compensation during the year ended December 31, 2006. Further, no member
        of the
        Company = s
        management has been granted any option or stock appreciation rights.
        Accordingly, no tables relating to such items have been included within this
        Item.
 
 There
        are
        no present plans whereby the Company will issue any of its securities to
        management, promoters, their affiliates or associates in consideration of
        services rendered or otherwise, except as described herein.
 
 **Compensation
        of directors**
 
 The
        Company has no arrangement for compensating its directors for their services
        as
        directors or for serving on any committees. However, directors may be
        compensated for services which they render as officers and/or as employees
        of
        the Company.
 
 **Employment
        contracts and termination of employment and change-in-control** **arrangements**
 
 There
        are
        no employment contracts, compensatory plans or arrangements, including payments
        to be received from the
        Company with
        respect to any executive officer of the Company which would in any way result
        in
        payments to any such person because of his or her resignation, retirement
        or
        other termination of employment with the Company or its subsidiary, any change
        in control of the Company or a change in the person's responsibilities following
        a change in control of the Company.
  32
  Nor
        are
        there any agreements or understandings for any director or executive officer
        to
        resign at the request of another person. None of the Company = s
        directors or executive officers is acting on behalf of or will act at the
        direction of any other person.
 
 The
        Company may enter into employment agreements with some of its officers in
        the
        near future but no definite terms have been agreed to yet.
 
 **Compensation
        pursuant to plans; pension table**
 
 There
        were no stock awards, restricted stock awards, stock options, stock appreciation
        rights, long-term incentive plan compensation or similar rights granted to
        any
        of our officers or directors. None of our officers or directors presently
        holds
        directly any stock options or stock purchase rights. We have no retirement,
        pension, profit sharing, or other plan covering any of our officers and
        directors.
 
 We
        have
        adopted no formal stock option plans for our officers, directors and/or
        employees. We reserve the right to adopt one or more stock options plans
        in the
        future. Presently we have no plans to issue additional shares of our common
        or
        preferred stock or options to acquire the same to our officers, directors
        or
        their affiliates or associates.
 
 **Other
        compensation**
 
 None.
  **Item
        11. Security Ownership of Certain Beneficial Owners and Management and** **Related
        Stockholder Matters**
 
 The
        following table sets forth the share holders of those persons who are known
        to
        the Company to be the beneficial owners of more than five percent (5.0%)
        of the
        Company’s common stock and of the share holdings of the Company’s directors and
        executive officers as of April 13, 2007. Each of these persons has sole
        investment and sole voting power over the shares indicated.
 
 All
        share
        amounts and percentages have been adjusted to reflect the four shares for
        one (4
        for 1) share forward stock split and the issuance of shares for the MedaCure
        acquisition. Percentages are based on 16,760,199 shares issued and outstanding.
  **Name
                      and Address**
                  
                  **Number
                      of Shares**
                  
                  **Percent****(1)***5%
                      Beneficial Owners*:The
                      Dastrup Family Trust
                  
                  
                  7,911,673
                  (2)
                  
                  47.2
                  %Vastmann
                      Investment Partners, LLC
                  
                  
                  886,667
                  (3)
                  
                  5.3
                  %*Directors
                      and Executive Officers*:Lincoln
                      Dastrup
                  
                  
                  7,911,673
                  (4)
                  
                  47.2
                  %Linda
                      Dastrup
                  
                  
                  7,911,673
                  (5)
                  
                  47.2
                  %Jarom
                      Dastrup
                  
                  
                  1,966,667
                  (6)
                  
                  11.7
                  %All
                      directors and executive officers as a group (3 persons)
                  
                  
                  9,878,340
                  (7)
                  
                  58.9
                  %
  
 (1)
              Percentage
                  ownership is based on 16,760,199 shares outstanding. Percentage
                  is
                  calculated for each individual listed based upon their beneficial
                  ownership of shares, although ownership may be shared with others,
                  such as
                  the Dastrup Family Trust.
  33
  (2)
              The
                  Dastrup Family Trust is a family trust of which Lincoln Dastrup
                  and Linda
                  Dastrup are the trustees with voting and dispositive power over
                  the
                  trust.
 (3)
                  Vastmann
                      Investment Partners is a limited liability company that is
                      one-third owned
                      by Jarom Dastrup and over which he has voting and dispositive
                      control.
 (4)
              Mr.
                  Dastrup’s shares are held in the name of The Dastrup Family Trust, of
                  which Mr. Dastrup is a trustee and, as indicated above, and which
                  holds
                  7,911,673 shares.(5)
              Mrs.
                  Dastrup’s shares are held in the name of The Dastrup Family Trust, of
                  which Mrs. Dastrup is a trustee and, as indicated above, and which
                  holds
                  7,911,673 shares.
 (6)
              Amount
                  shown includes shares that are owned by Vastmann Investment Partners,
                  LLC,
                  of which Jarom Dastrup owns a one-third interest.(7)
              Amount
                  shown represents the holdings of The Dastrup Family Trust, of which
                  Lincoln Dastrup and Linda Dastrup are trustees, Jarom Dastrup and
                  Vastmann
                  Investment Partners, LLC that is one-third owned by Jarom
                  Dastrup.
 
 All
        common shares held by the officers, directors and principal shareholders
        listed
        above are A restricted
        or control securities @ and are
        subject to limitations on resale. The shares may be sold in compliance with
        the
        requirements of Rule 144, after a minimum one year holding period has been
        met.
 
 Rule
        13d-3 generally provides that beneficial owners of securities include any
        person
        who directly or indirectly has or shares, voting power and/or investment
        power
        with respect to such securities; and any person who has the right to acquire
        beneficial ownership of such security within 60 days.
 
 Any
        securities not outstanding which are subject to options, warrants or conversion
        privileges exercisable within 60 days are treated as outstanding for the
        purpose
        of computing the percentage of outstanding securities owned by that person.
        But
        such securities are not treated as outstanding for the purpose of computing
        the
        percentage of the class owned by any other person.
 
 **Changes
        in control**
 
 There
        are
        no present arrangements or pledges of the Company = s
        securities, known to management, which may result in a change in control
        of the
        Company.
  **Item
        12. Certain Relationships and Related Transactions**
 
 **Transactions
        with management and others**
 
 Except
        as
        indicated below, and for the periods indicated, there were no material
        transactions, or series of similar transactions, during the last three fiscal
        years ended December 31, 2006, or since December 31, 2006, or any currently
        proposed transactions, or series of similar transactions, to which the Company
        was or is to be party, in which the amount involved exceeds the lesser of
        $120,000 or one percent of the average of the company’s total assets at year-end
        for the last three fiscal years, and in which any director or executive officer,
        or any security holder who is known by the Company to own of record or
        beneficially more than 5% of any class of the Company's common stock, or
        any
        member of the immediate family of any of the foregoing persons, has an interest,
        other than the following:
  (1)
          During the year ended December 31, 2006 the Company has at various times
          made
          temporary loans to the Company’s Chief Executive Officer. The outstanding
          balance of these loans at December 31, 2006, including accrued interest,
          is
          $17,415.
  34
  (2)
        On
        May 20, 2005, the board of directors authorized the issuance of a total of
        1,333,336 post-split shares (“the issuance”) of common stock, separately, to
        Lane S. Clissold (666,668) and Steven D. Moulton (666,668), two of the Company’s
        former officers. The shares were issued in consideration for Messrs. Clissold's
        and Moulton's agreement to convert into shares of common stock all amounts
        due
        and owing to them resulting from loans and/or advances made to the Company.
        As a
        result of the issuance, the loans and/or advances made by Messrs. Clissold
        and
        Moulton to the Company through May 15, 2005, and all accrued interest thereon,
        were deemed to be paid in full. The shares were valued at $0.1935 per share
        for
        total consideration of $64,500
 
 (3)
        In
        October 2006 the Company issued an aggregate of approximately 12,342,239
        shares
        of common stock as consideration for the acquisition of Medacure International,
        Inc.
 
 **Potential
        Conflict of Interest**
 
 We
        have
        no formal conflict of interest policy in place regarding the possibility
        of our
        entering into transactions with affiliates. We lack such a policy because
        we
        believe it highly unlikely that we will acquire or do business with an entity
        in
        which members of our management have an ownership interest, directly or
        indirectly. However, in the event a related party transaction did arise,
        it
        would almost certainly be ratified by a disinterested board of directors
        and,
        possibly, by the stockholders if deemed necessary. Management intends do
        whatever is necessary to fully and completely comply with Nevada corporate
        law
        relating to conflicting interest transactions as set forth in the Nevada
        Revised
        Statutes.
  **Item
        13. Exhibits**
  Exhibit
                    No
                
                Exhibit
                    Name2.1(1)
                
                Agreement
                    and Plan of Merger by and among Jump’n Jax, Inc., CuraTech Acquisitions,
                    Inc. and MedaCure International, Inc., including
                    Addendum3.1(2)
                
                Articles
                    of Incorporation3.2(2)
                
                By-Laws21.1(3)
                
                List
                    of Subsidiaries31.1
                
                Certification
                    of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley
                    Act of 200231.2
                
                Certification
                    of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley
                    Act of 200232.1
                
                Certificate
                    of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley
                    Act of 200232.2
                
                Certificate
                    of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley
                    Act of 2002
  Summaries
                    of all exhibits contained within this report are modified in
                    their
                    entirety by reference to these exhibits.
 
 (1)
                Exhibit
                    2.1 is incorporated by reference from the Company’s Form 8-K Current
                    Report filed June 22, 2006 as Exhibit 2.1(2)
                Exhibit
                    3.1 and 3.2 are incorporated by reference from the Company’s SB-2
                    Registration Statement filed September 9, 2004 as Exhibits 3.1
                    and
                    3.2(3)
                Exhibit
                    21.2 is incorporated by reference from the Company’s Form 8-K Current
                    Report filed December 21,
                    2006
  35
  **Item
        14. Principal Accountants Fees and Services**
 
 We
        do not
        have an audit committee and as a result our entire board of directors performs
        the duties of an audit committee. Our board of directors will approve in
        advance
        the scope and cost of the engagement of an auditor before the auditor renders
        audit and non-audit services. As a result, we do not rely on pre-approval
        policies and procedures.
 
 **Audit
        Fees**
 
 The
        aggregate fees billed by our former independent auditors of record, HJ &
Associates, for professional services rendered for the audit of our annual
        financial statements included in our prior annual report and in our registration
        statement on Form SB-2 for the fiscal year ended December 31, 2005, and for
        the
        review of quarterly financial statements dated March 31, 2006 were approximately
        $6,000. The aggregate fees billed by our current independent auditors of
        record,
        Moore & Associates, for professional services rendered for the quarterly
        reviews of our financial statements dated June 30, 2006 and September 30,
        2006
        and for the audit of our annual financial statements included in this report
        were approximately $9,131.00.
 
 **Audit
        Related Fees**
 
 For
        the
        fiscal years ended December 31, 2006 and 2005, there were no fees billed
        for
        assurance and related services by HJ & Associates or Moore & Associates
        relating to the performance of the audit of our financial statements which
        are
        not reported under the caption "Audit Fees" above.
 
 **Tax
        Fees**
 
 For
        the
        fiscal years ended December 31, 2006 and 2005, there were no fees billed
        by HJ
& Associates or Moore & Associates for tax compliance, tax advice and
        tax planning.
 
 We
        do not
        use Moore & Associates, and have not used H J & Associates for financial
        information system design and implementation. These services, which include
        designing or implementing a system that aggregates source data underlying
        the
        financial statements or generates information that is significant to our
        financial statements, are provided internally or by other service providers.
        We
        do not engage Moore & Associates or H J & Associates to provide
        compliance outsourcing services.
 
 The
        board
        of directors has considered the nature and amount of fees billed by Moore
&
Associates and H J & Associates and believes that the provision of services
        for activities unrelated to the audit is compatible with maintaining HJ &
Associates' independence.
  36
  **SIGNATURES**
 
 In
        accordance with Section 13 or 15(d) of the Exchange Act, the Registrant caused
        this report to be signed on its behalf by the undersigned, thereunto duly
        authorized.
  CuraTech
                  Industries, Inc.By:
              /s/
                  Lincoln M. DastrupLincoln
                  M. DastrupChief
                  Executive Officer
  Dated:
          September 13, 2007
 
 In
        accordance with the Exchange Act, this report has been signed below by the
        following persons on behalf of the Registrant and in the capacities and on
        the
        dates indicated.
  Signature
                
                Title
                
                Date/s/
                    Lincoln M. DastrupLincoln
                    M. Dastrup
                
                President,
                    Chief
                  Executive
                      Officer and
                
                September
                    13, 2007Chief
                    Financial Officer/s/
                    Jarom L. DastrupJarom
                    L. Dastrup
                
                Director
                    and Executive
                  Vice
                      President
                
                September
                    13, 2007/s/
                    Linda L. DastrupLinda
                    L. Dastrup
                
                Director
                    and Treasurer
                
                September
                    13, 2007
  37